Synthetic Polypeptides-Downie et al.
S ummary: Norgestrel in a dose of 50 ug. was administered daily to 188 women during 2,250 menstrual cycles. Only two pregnancies occurred because of failure of the method, giving a failure rate of 1.1 pregnancies per 100 woman-years. The method was acceptable to most of the subjects, and side-effects, other than menstrual irregularity, were minimal; 68% of the cycles were 28 ±5 days in length and 21% were less than 23 days. There did not appear to be any increased incidence of amenorrhoea. The antifertility action of continuous administration of low doses of progestogen may be due to an effect on corpus luteum function, in addition to the effects on cervical mucus, endometrium, and tubal transport of ova. The optimum dose of norgestrel appears to be in the range of 50-75 /Ag./day. Introduction Martinez-Manautou et al. (1966 , 1967 showed that continuous dosage with 0.5 mg. of chlormadinone acetate daily exerted an antifertility effect, though ovulation was not always inhibited. In a trial involving over 900 women for more than 8,000 cycles only one pregnancy occurred that could be attributed to a failure of the method, giving a pregnancy rate of 0.2 per 100 woman-years. The Sims-Huhner test was negative in 80% of 115 women studied, and 65% of the endometrial biopsies from 202 women showed normal or irregular secretory patterns indicative of ovulation. Other studies in which the same dose of chlormadinone was used have shown a failure rate of 4.6 per 100 woman-years (Zafiartu et al., 1968) . The antifertility effect of low-dose progestogen treatment was ascribed to effects on the uterine endometrium or to effects on cervical mucus. The above studies involving chlormadinone acetate were carried out on South and Central American women, and it was felt desirable to test the acceptability of this type of method in British women. The results of the present paper show that norgestrel (13,3-ethyl-17a-ethynyl-17,3-hydroxygon- 
Subjects and Methods
The patients admitted to the trial were seen regularly at monthly intervals ; at the initial attendance the subjects were examined and information was obtaine4 regarding parity, menstrual history, previous methods of contraception, and general medical history. Care (Bagshawe et al., 1966 (Fotherby, 1962) . Subject 9 excreted amounts of pregnanediol throughout the entire cycle varying from 2 to 2.5 mg./day and there was no definite increase in the second half of the cycle. Of the three subjects in Table II for whom the excretion of luteinizing hormone was measured daily, Subject 6 showed a marked rise in luteinizing hormone excretion (Fig. 2) , Subject 9 showed a possible rise, and Subject 7 showed no increase. irregular menstruation which occurred in many patients. However, this aspect of the method should not be unduly stressed.
The combined oestrogen and progestin contraceptive pills produce a regular cycle with very little breakthrough bleeding, and the irregular menstruation experienced by some women before starting treatment usually disappears on starting treatment with a combined preparation. The incidence of irregular menstruation, therefore, in women taking the low-dose contraceptives should be compared with the normal incidence of menstrual irregularities. The variation of menstrual cycle length has recently been discussed by Treloar et al. (1967) , who compared their results with those recorded in 10 other studies. In Fig. 1 the cycle lengths recorded in the patients receiving norgestrel have been superimposed on those reported by Treloar et al. It will be seen that the menstrual cycle lengths of the patients in this study followed very closely the normal curves, except at the lower end. This shows clearly that in women taking a low-dose contraceptive there is a higher than normal incidence of cycles less than 23 days in length, but that the incidence of shorter cycles is increased by only about 10% above the normal level. There was no increased incidence of amenorrhoea in these subjects such as seems to occur in subjects taking chlormadinone acetate. There is no doubt that in the great majority of patients the method was acceptable and few complained even on direct questioning.
Various suggestions have been made regarding the mode of action of the low-dose progestogen treatment in preventing conception. The possible modes of action include (1) Effects on the cervical mucus rendering it impenetrable to spermatozoa Mason et al., 1967 ; Zafiartu et al.., 1968) . (2) Effects on the endometrium as shown by the increased incidence of irregular bleeding in subjects taking low-dose progestins and also from results of the endometrial biopsies reported in this paper and those reported by Martinez-Manautou et al. (1967) and Zafiartu et at. (1968) . The effect on the endometrium could be a direct one resulting from the administered progestin or it may be an indirect one. It has been shown in animal studies that after the intravenous administration of 14C-norgestrel less than 0.1% of the dose is present in the uterus two to five hours later (Kamyab et al., 1967) . (3) The possible effects on the tubal transport of ova.
A fourth point of action is suggested by the results presented in this paper, showing that in half the treated subjects pregnanediol excretion during the luteal phase was low and that the levels found were much lower than those associated with the luteal phase of a normal menstrual cycle. It is unlikely that the dose of norgestrel (50 jug.) used in these studies would be sufficient to inhibit ovulation. Of the three subjects in whorh luteinizing hormone excretion was measured one definitely and one possibly showed an increase, suggesting that ovulation might have occurred. The administered progestin may therefore interfere with the functioning and formation of the corpus luteum, resulting in an inhibition of ovarian steroid secretion. Preliminary studies in which the ovary has been examined at laparotomy in subjects treated with 50 M.g. of norgestrel daily showed that in all cases the corpus luteum was histologically normal.
As with chlormadinone acetate the daily dose required seems to be fairly critical ( (Edgren et al., 1963) , so that it should be possible to obtain the same contraceptive efficiency with 25-35 M-tg. of the d norgestrel.
One of the main advantages of the above method is the absence of an oestrogen in the pill. The latter is generally regarded as being responsible for most of the side-effects associated with the combined oral contraceptive pill, and may be the cause of the more serious side-effects-for example, deep-vein thrombosis and pulmonary embolism (Brit. med. Y., 1968) . Un- like some other derivatives of 17a-ethynyl-19-testosterone, but like chlormadinone, norgestrel seems to have little oestrogenic effect.
